Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase

Gynecologic Oncology

Volumn 140, Issue 3, 2016, Pages 457-462

  Grabowski, Jacek P ^a,h   Harter, Philipp ^a   Heitz, Florian ^a   Pujade Lauraine, Eric ^b   Reuss, Alexander ^c   Kristensen, Gunnar ^d   Ray Coquard, Isabelle ^e   Heitz, Julia ^f   Traut, Alexander ^a   Pfisterer, Jacobus ^g   Du Bois, Andreas ^a  

^a KLINIKEN ESSEN MITTE   (Germany)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITÉ DE LYON   (France)

^f Klinikum Duisburg   (Germany)

^g Gynecologic Oncology Center Kiel   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

High grade serous ovarian cancer; Low grade serous ovarian cancer; Objective response; Platinum chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; EPIRUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN; DEOXYCYTIDINE;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER SURGERY; CASE CONTROL STUDY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DATA BASE; EXPLORATORY RESEARCH; FEMALE; HUMAN; LOW GRADE SEROUS OVARIAN CANCER; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; YOUNG ADULT; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; DISEASE FREE SURVIVAL; MINIMAL RESIDUAL DISEASE; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; CYTOREDUCTION SURGICAL PROCEDURES; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM, RESIDUAL; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TOPOTECAN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84959474280     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.01.022     Document Type: Article

References (34)

1. A. Malpica, M.T. Deavers, K. Lu, D.C. Bodurka, E.N. Atkinson, D.M. Gershenson, and et al. Grading ovarian serous carcinoma using two-tier system Am. J. Surg. Pathol. 28 2004 496 504
2. I.M. Shih, and R.J. Kurman Ovarian tumorigenesis. A proposed model based on morphological and molecular genetic analysis Am. J. Pathol. 164 2004 1511 1518
3. H.E. Russell, and W.G. McCluggage A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes J. Pathol. 203 2004 617 619
4. G. Singer, R.J. Kurman, H.W. Chang, S.K. Cho, and I.M. Shih Diverse tumorigenic pathways in ovarian serous carcinoma Am. J. Pathol. 160 2002 1223 1228
5. G. Singer, I.M. Shih, A. Truskinovsky, H. Umudum, and R.J. Kurman Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma Int. J. Gynecol. Pathol. 22 2003 37 41
6. G. Singer, R. Stohr, L. Cope, R. Dehari, A. Hartmann, D.F. Cao, and et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low and high grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation Am. J. Surg. Pathol. 29 2005 218 224
7. K.M. Schmeler, and D.M. Gershenson Low-grade serous ovarian cancer: a unique disease Curr. Oncol. Rep. 10 2008 519 523
8. I. Meinhold-Heerlein, D. Bauerschlag, F. Hilpert, P. Dimitrov, L.M. Sapinoso, M. Orlowska-Volk, and et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential Oncogene 24 2005 1053 1065
9. A. du Bois, A. Reuss, E. Pujade-Lauraine, P. Harter, I. Ray-Coquard, and J. Pfisterer The role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer. A combined exploratory analysis of three prospectively randomized phase III multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115 6 2009 1234 1244
10. A. du Bois, J. Rochon, C. Lamparter, and J. Pfisterer The Quality Assurance Program of the AGO Organkommission OVAR (QS-OVAR): pattern of care and reality in Germany 2001 Zentralbl. Gynakol. 127 2005 9 17
11. H.J. Mackay, M.F. Brady, A.M. Oza, A. Reuss, E. Pujade-Lauraine, A.M. Swart, and et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer Int. J. Gynecol. Cancer 20 2010 945 952
12. K.M. Schmeler, C.C. Sun, D.C. Bodurka, M.T. Deavers, A. Malpica, R.L. Coleman, and et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum Gynecol. Oncol. 108 2008 510 514
13. R.E. Bristow, D.R. Gossett, D.R. Shook, M.L. Zahurak, R.S. Tomacruz, D.K. Armstrong, and et al. Recurrent micropapillary serous ovarian carcinoma Cancer 95 2002 791 800
14. D.M. Gershenson, C.C. Sun, D. Bodurka, R.L. Coleman, K.H. Lu, A.K. Sood, and et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant Gynecol. Oncol. 114 2009 48 52
15. A. du Bois, H.J. Lück, W. Meier, H.P. Adams, V. Möbus, S. Costa, and et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J. Natl. Cancer Inst. 95 2003 1320 1330
16. A. du Bois, B. Weber, J. Rochon, W. Meier, A. Goupil, S. Olbricht, and et al. Addition of epirubicin as third drug to carboplatin-paclitaxel in firstline treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens J. Clin. Oncol. 24 2006 1127 1135
17. J. Pfisterer, B. Weber, A. Reuss, R. Kimmig, A. du Bois, U. Wagner, and et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO J. Natl. Cancer Inst. 98 2006 1036 1045
18. A. du Bois, J. Herstedt, A.C. Hardy-Bessard, H.H. Müller, P. Harter, G. Kristensen, and et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first line treatment of epithelial ovarian cancer J. Clin. Oncol. 28 2010 4162 4169
19. World Health Organization WHO Handbook for Reporting Results of Cancer Treatment 1979 World Health Organization Geneva (Switzerland) (Offset Publication No. 48). (Available from: http://whqlibdoc.who.int/publications/9241700483.pdf)
20. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein, and et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States. National Cancer Institute of Canada J. Natl. Cancer Inst. 92 2000 205 216
21. S.C. Plaxe Epidemiology of low-grade serous ovarian cancer Am J Obstet Gynecol 198 2008 459.e1 459.e8 [discussion 459.e8-9]
22. E.K. Crane, C.C. Sun, R. PT, S. KM, A. Malpica, and G. DM The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer Gynecol Oncol 2014 (PMID: 25448453)
23. D.M. Gershenson, C.C. Sun, K.H. Lu, R.L. Coleman, A.K. Sood, A. Malpica, and et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary Obstet. Gynecol. 108 2006 361 368
24. D.M. Gershenson, C.C. Sun, R.B. Iyer, A.L. Malpica, J.J. Kavanagh, D.C. Bodurka, and et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum Gynecol. Oncol. 125 2012 661 666
25. P. Harter, A. du Bois, C. Schade-Brittinger, A. Burges, K. Wollschlaeger, M. Gropp, and et al. Non-enrolment of ovarian cancer patients in clinical trials: reasons and background Ann. Oncol. 16 2005 1801 1805
26. S. Kommoss, J. Pfisterer, A. Reuss, J. Diebold, S. Hauptmann, C. Schmidt, and et al. Specialized pathology review in patients with ovarian cancer: results from a prospective study Int. J. Gynecol. Cancer 23 2013 1376 1382
27. S. Kommoss, J. Pfisterer, A. du Bois, D. Schmidt, and F. Kommoss Specialized histopathological second opinion of advanced ovarian cancer. Experiences with collectives from prospective randomized phase III studies Pathologe 35 2014 355 360
28. G. Singer, R. Oldt III, Y. Cohen, B.G. Wang, D. Sidransky, R.J. Kurman, and et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J. Natl. Cancer Inst. 95 2003 484 486
29. G. Singer, I.M. Shih, A. Truskinovsky, H. Umudum, and R.J. Kurman Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor) Int. J. Gynecol. Pathol. 22 2003 37 41
30. C.Y. Hsu, R. Bristow, M.S. Cha, B.G. Wang, C.L. Ho, R.J. Kurman, and et al. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas Clin. Cancer Res. 10 2004 6432 6436
31. G. Pohl, C.L. Ho, R.J. Kurman, R. Bristow, T.L. Wang, and I.M. Shih Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations Cancer Res. 65 2005 1994 2000
32. N. Nakayama, K. Nakayama, S. Yeasmin, M. Ishibashi, A. Katagiri, K. Iida, and et al. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer Br. J. Cancer 99 2008 2020 2028
33. I. Romero, C.C. Sun, K.K. Wong, R.C. Bast, and D.M. Gershenson Low-grade serous carcinoma: new concepts and emerging therapies Gynecol. Oncol. 130 2013 660 666
34. J. Farley, W.E. Brady, L.H.A. Vathipadiekal, R. Coleman, M.A. Morgan, and et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study Lancet Oncol. 14 2013 134 140